Cargando…
mTORC1 restrains adipocyte lipolysis to prevent systemic hyperlipidemia
OBJECTIVE: Pharmacological agents targeting the mTOR complexes are used clinically as immunosuppressants and anticancer agents and can extend the lifespan of model organisms. An undesirable side effect of these drugs is hyperlipidemia. Although multiple roles have been described for mTOR complex 1 (...
Autores principales: | Paolella, Lauren M., Mukherjee, Sarmistha, Tran, Cassie M., Bellaver, Bruna, Hugo, Mindy, Luongo, Timothy S., Shewale, Swapnil V., Lu, Wenyun, Chellappa, Karthikeyani, Baur, Joseph A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6961719/ https://www.ncbi.nlm.nih.gov/pubmed/32029223 http://dx.doi.org/10.1016/j.molmet.2019.12.003 |
Ejemplares similares
-
Hypothalamic mTORC2 is essential for metabolic health and longevity
por: Chellappa, Karthikeyani, et al.
Publicado: (2019) -
SIRT3 is required for liver regeneration but not for the beneficial effect of nicotinamide riboside
por: Mukherjee, Sarmistha, et al.
Publicado: (2021) -
MDM4 actively restrains cytoplasmic mTORC1 by sensing nutrient availability
por: Mancini, Francesca, et al.
Publicado: (2017) -
Dynamic Adipocyte Phosphoproteome Reveals that Akt Directly Regulates mTORC2
por: Humphrey, Sean J., et al.
Publicado: (2013) -
mTORC1 inhibition uncouples lipolysis and thermogenesis in white adipose tissue to contribute to alcoholic liver disease
por: Song, Qing, et al.
Publicado: (2023)